Disproportionate Intrauterine Growth Intervention Trial At Term: DIGITAT

Kim E. Boers*, Denise Bijlenga, Ben W.J. Mol, Saskia LeCessie, Erwin Birnie, Marielle G. van Pampus, Rob H. Stigter, Kitty W.M. Bloemenkamp, Claudia A. van Meir, Joris A.M. van der Post, Dick J. Bekedam, Lucy S.M. Ribbert, Addie P. Drogtrop, Paulien C.M. van der Salm, Anjoke J.M. Huisjes, Christine Willekes, Frans J.M.E. Roumen, Hubertina C.J. Scheepers, Karin de Boer, Johannes J. DuvekotJim G. Thornton, Sicco A. Scherjon

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

23 Citations (Scopus)


Background: Around 80% of intrauterine growth restricted (IUGR) infants are born at term. They have an increase in perinatal mortality and morbidity including behavioral problems, minor developmental delay and spastic cerebral palsy. Management is controversial, in particular the decision whether to induce labour or await spontaneous delivery with strict fetal and maternal surveillance. We propose a randomised trial to compare effectiveness, costs and maternal quality of life for induction of labour versus expectant management in women with a suspected IUGR fetus at term. Methods/design: The proposed trial is a multi-centre randomised study in pregnant women who are suspected on clinical grounds of having an IUGR child at a gestational age between 36+0 and 41+0 weeks. After informed consent women will be randomly allocated to either induction of labour or expectant management with maternal and fetal monitoring. Randomisation will be web-based. The primary outcome measure will be a composite neonatal morbidity and mortality. Secondary outcomes will be severe maternal morbidity, maternal quality of life and costs. Moreover, we aim to assess neurodevelopmental and neurobehavioral outcome at two years as assessed by a postal enquiry (Child Behavioral Check List-CBCL and Ages and Stages Questionnaire-ASQ). Analysis will be by intention to treat. Quality of life analysis and a preference study will also be performed in the same study population. Health technology assessment with an economic analysis is part of this so called Digitat trial (Disproportionate Intrauterine Growth Intervention Trial At Term). The study aims to include 325 patients per arm. Discussion: This trial will provide evidence for which strategy is superior in terms of neonatal and maternal morbidity and mortality, costs and maternal quality of life aspects. This will be the first randomised trial for IUGR at term.

Original languageEnglish
Article number12
JournalBMC Pregnancy and Childbirth
Publication statusPublished - 10 Jul 2007


Dive into the research topics of 'Disproportionate Intrauterine Growth Intervention Trial At Term: DIGITAT'. Together they form a unique fingerprint.

Cite this